Philadelphia, Pennsylvania--(Newsfile Corp. - March 9, 2026) - Kehoe Law Firm, P.C. is investigating potential breach of fiduciary duty claims on behalf of investors of Universal Health Services, Inc. ("Universal Health") (NYSE: UHS).

Philadelphia, Pennsylvania--(Newsfile Corp. - March 9, 2026) - Kehoe Law Firm, P.C. is investigating potential breach of fiduciary duty claims on behalf of investors of Universal Health Services, Inc. ("Universal Health") (NYSE: UHS).

Novo Nordisk ended its dispute with Hims & Hers Health, enabling Wegovy distribution across a digital platform serving roughly 2.5 million subscribers. Novo Nordisk maintains exceptional profitability with an 82.41% gross margin and 45.50% EBIT margin, significantly exceeding sector medians. FY25 net profit reached DKK 100 billion while operating cash flow approached DKK 120 billion, supporting major CapEx, acquisitions, and shareholder returns.

Novo Nordisk ended its dispute with Hims & Hers Health, enabling Wegovy distribution across a digital platform serving roughly 2.5 million subscribers. Novo Nordisk maintains exceptional profitability with an 82.41% gross margin and 45.50% EBIT margin, significantly exceeding sector medians. FY25 net profit reached DKK 100 billion while operating cash flow approached DKK 120 billion, supporting major CapEx, acquisitions, and shareholder returns.

ONDS lands $6M in counter-drone orders from Middle East defense customers, deploying cyber-RF systems that detect, track and take control of hostile drones.

ONDS lands $6M in counter-drone orders from Middle East defense customers, deploying cyber-RF systems that detect, track and take control of hostile drones.

OVV benefits from focused Permian and Montney operations, productivity gains and stronger capital returns, though price volatility and integration complexities remain key risks.

OVV benefits from focused Permian and Montney operations, productivity gains and stronger capital returns, though price volatility and integration complexities remain key risks.

SIMO to unveil AI-optimized boot storage and enterprise SSD controllers at Embedded World 2026, targeting industrial systems, automotive AI computing and data center workloads.

SIMO to unveil AI-optimized boot storage and enterprise SSD controllers at Embedded World 2026, targeting industrial systems, automotive AI computing and data center workloads.

Comfort Systems USA, Inc. FIX is benefiting from strong construction demand that is improving visibility into future project activity. Continued investment in technology infrastructure, institutional facilities and industrial development is supporting a steady pipeline of opportunities.

Comfort Systems USA, Inc. FIX is benefiting from strong construction demand that is improving visibility into future project activity. Continued investment in technology infrastructure, institutional facilities and industrial development is supporting a steady pipeline of opportunities.

Philadelphia, Pennsylvania--(Newsfile Corp. - March 9, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company") on behalf of investors who purchased American Depositary Shares ("ADS") issued by Mereo during the period from June 5, 2023 through December 26, 2025 (the "Class Period"). Investor Deadline: Investors who purchased Mereo securities during the Class Period may, no later than April 6, 2026, seek to be appointed as a lead plaintiff representative of the class.

Philadelphia, Pennsylvania--(Newsfile Corp. - March 9, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company") on behalf of investors who purchased American Depositary Shares ("ADS") issued by Mereo during the period from June 5, 2023 through December 26, 2025 (the "Class Period"). Investor Deadline: Investors who purchased Mereo securities during the Class Period may, no later than April 6, 2026, seek to be appointed as a lead plaintiff representative of the class.

LOS ANGELES, March 09, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bath & Body Works, Inc. (“Bath & Body Works” or “the Company”) (NYSE: BBWI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between June 4, 2024 and November 19, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before March 16, 2026.

LOS ANGELES, March 09, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bath & Body Works, Inc. (“Bath & Body Works” or “the Company”) (NYSE: BBWI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between June 4, 2024 and November 19, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before March 16, 2026.

HONG KONG, March 9, 2026 /PRNewswire/ -- Aurelion Inc. (NASDAQ: AURE) ("Aurelion" or the "Company") today announced that it received a notification letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on March 5, 2026 notifying the Company that it has regained compliance with the Nasdaq Capital Market's minimum bid price requirement and that the matter is now closed. On April 1, 2025, the Company was first notified by Nasdaq of its failure to maintain a minimum closing bid price of at least $1.00 per share for 30 consecutive trading days under Nasdaq Listing …

HONG KONG, March 9, 2026 /PRNewswire/ -- Aurelion Inc. (NASDAQ: AURE) ("Aurelion" or the "Company") today announced that it received a notification letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on March 5, 2026 notifying the Company that it has regained compliance with the Nasdaq Capital Market's minimum bid price requirement and that the matter is now closed. On April 1, 2025, the Company was first notified by Nasdaq of its failure to maintain a minimum closing bid price of at least $1.00 per share for 30 consecutive trading days under Nasdaq Listing …

Abbott Laboratories (ABT) remains a Buy, with the stock undervalued at $109.56 despite recent execution missteps and Nutrition segment weakness. Core Devices and Diagnostics segments continue to deliver high single-digit sales growth and double-digit EPS growth, supporting the investment thesis. Nutrition remains a key risk, but management expects a turnaround in the second half; Exact Sciences acquisition could add a new high-growth vertical.

Abbott Laboratories (ABT) remains a Buy, with the stock undervalued at $109.56 despite recent execution missteps and Nutrition segment weakness. Core Devices and Diagnostics segments continue to deliver high single-digit sales growth and double-digit EPS growth, supporting the investment thesis. Nutrition remains a key risk, but management expects a turnaround in the second half; Exact Sciences acquisition could add a new high-growth vertical.